Romosozumab, which is approved for the treatment of osteoporosis, has a dual-action mechanism that promotes bone formation and inhibits bone resorption. However, its association with an increased risk of major adverse cardiovascular events, as highlighted in the ARCH I study, raises concerns. The underlying pathophysiological mechanisms, possibly involving changes in platelet dynamics, are yet to be fully elucidated. Herein, we present a case of a 60-year-old Korean woman diagnosed with immune thrombocytopenic purpura and new-onset osteoporosis, who was treated with romosozumab. Subsequent to the administration of romosozumab, there was a notable elevation in her platelet count. This observation warrants further investigation into the off-target effects of romosozumab, especially its impact on hematopoietic stem cell function and platelet dynamics. This case accentuates the imperative for more comprehensive research into the systemic effects of romosozumab, particularly its involvement in hematopoiesis and cardiovascular risk, to thoroughly understand its extensive implications for patient health.
Background Romosozumab has shown significant improvement in bone mineral density (BMD) in previously reported trials. However, BMD reflects only bone strength and does not offer insight into the bone microarchitecture. The trabecular bone score (TBS) is a non-invasive tool used to assess bone microarchitecture. Several previous studies have evaluated the efficacy of anti-osteoporotic agents using the TBS. However, data regarding the potency of romosozumab based on the TBS is lacking. This retrospective observational cohort study demonstrated the impact of romosozumab use on the TBS.
Methods The primary outcome was the percentage change in the TBS from baseline to post-treatment. Postmenopausal osteoporosis patients were followed up for 6 and 12 months after romosozumab (210 mg monthly, N =10) and denosumab (60 mg every 6 months, N=21) or ibandronate (150 mg monthly, N=24) treatments, respectively. Patients who had previously used osteoporosis medications were included, if any the washout period was sufficient.
Results The percentage change in TBS from baseline to post-treatment was 2.53±2.98% (6 months, N=10; P=0.04), 0.59%±3.26% (12 months, N=21; P=0.48), and -0.45±3.66% (12 months, N=24; P=0.51) in the romosozumab, denosumab, and ibandronate groups, respectively. Romosozumab demonstrated a noticeable increase in TBS, although it did not reach the least significant change (5.8%) in TBS.
Conclusions Romosozumab improved the TBS in postmenopausal women with osteoporosis. TBS may be potentially useful for monitoring romosozumab treatment.
Citations
Citations to this article as recorded by
1. Very short-term monitoring of Romosozumab longitudinal effects in a cohort of postmenopausal women by means of Radiofrequency Echographic Multi-Spectrometry (REMS) technology Angelo Semeraro, Angela Chialà, Andrea Carafa, Rosalinda Fanizzi, Elisabetta Di Tano, Maria Palmisano, Carmela Santoro, Federica Dibenedetto, Nicola Napoli Aging Clinical and Experimental Research.2026;[Epub] CrossRef
2. Romosozumab's Effect on Bone Mineral Density in Patients with Osteoporosis: A Systematic Review and Meta-Analysis Hooman Yahyazadeh, Tahereh Farkhondeh, Abolfazl Bagherifard, Karo Khosravi, Reza Ahmadi, Hamed Aramjoo, Babak Roshanravan, Saeed Samarghandian Current Medicinal Chemistry.2026; 33(14): 2794. CrossRef
3. Romosozumab improves microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis Michael R McClung, Donald Betah, Benjamin Z Leder, David L Kendler, Mary Oates, Jen Timoshanko, Zhenxun Wang Journal of Bone and Mineral Research.2025; 40(2): 193. CrossRef
4. Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass Seunghyun Lee, Namki Hong, Sung Joon Cho, Sungjae Shin, Yumie Rhee Osteoporosis International.2025; 36(2): 323. CrossRef
5. Romosozumab Improves Tissue Thickness–Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes Serge Ferrari, Donald Betah, Robert G Feldman, Bente L Langdahl, Mary Oates, Jen Timoshanko, Zhenxun Wang, Ruban Dhaliwal The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): 2861. CrossRef
6. Trabecular Bone Score: From Over a Decade of Evidence to a Connected
Bone Health Ecosystem Karen Hind, Madeleine Davies, Elena Gonzalez-Rodriguez, Didier Hans Osteologie.2025; 34(03): 213. CrossRef
7. Efficacy comparison of 6-month romosozumab plus denosumab versus 12-month romosozumab in Koreans Seung-Eun Lee, Seong Hee Ahn, Beom-Jun Kim, Seung Hun Lee, Ha Young Kim, Seongbin Hong, Jung-Min Koh European Journal of Endocrinology.2025; 193(5): 527. CrossRef
8. Prognostic value of trabecular bone score for major osteoporotic fractures in patients with radiographic axial spondyloarthritis: a 3-year prospective cohort study Paweł Żuchowski, Marta Dura, Daniel Jeka, Katarzyna Gajewicz-Sawicka, Michał Kułakowski, Burkhard Muche Rheumatology International.2025;[Epub] CrossRef
9. Clinical Use of Trabecular Bone Score: The 2023 ISCD Official Positions Heenam Goel, Neil Binkley, Miranda Boggild, Wing P. Chan, William D. Leslie, Eugene McCloskey, Sarah L. Morgan, Barbara C. Silva, Angela M. Cheung Journal of Clinical Densitometry.2024; 27(1): 101452. CrossRef
10. Update on the utility of trabecular bone score (TBS) in clinical practice for the management of osteoporosis: a systematic review by the Egyptian Academy of Bone and Muscle Health Yasser El Miedany, Walaa Elwakil, Mohammed Hassan Abu-Zaid, Safaa Mahran Egyptian Rheumatology and Rehabilitation.2024;[Epub] CrossRef
11. Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial Chi Chiu Mok, Kar Li Chan, Sau Mei Tse, Sammy Pak Lam Chen, Kathryn Choon Beng Tan, Wai Han Ma Journal of Internal Medicine.2024; 296(6): 481. CrossRef
12. Trabecular Bone Score to Enhance Fracture Risk Prediction and Treatment Strategies in Osteoporosis Guillaume Gatineau, Didier Hans, Karen Hind Seminars in Musculoskeletal Radiology.2024; 28(05): 539. CrossRef
13. Il ruolo del Trabecular Bone Score (TBS) nella gestione dell’osteoporosi primaria e secondaria Fabio Bioletto, Massimo Procopio, Marco Barale L'Endocrinologo.2024; 25(6): 634. CrossRef
14. Incident Vertebral Fractures During Romosozumab Treatment in a Patient With a Pathogenic LRP5 Variant Evert F S van Velsen, Mark Wijnen, Galied S R Muradin, M Carola Zillikens JCEM Case Reports.2024;[Epub] CrossRef
15. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension Didier Hans, Michele McDermott, Shuang Huang, Min Kim, Enisa Shevroja, Michael McClung Osteoporosis International.2023; 34(6): 1075. CrossRef
16. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Disease Enisa Shevroja, Jean-Yves Reginster, Olivier Lamy, Nasser Al-Daghri, Manju Chandran, Anne-Laurence Demoux-Baiada, Lynn Kohlmeier, Marie-Paule Lecart, Daniel Messina, Bruno Muzzi Camargos, Juraj Payer, Sansin Tuzun, Nicola Veronese, Cyrus Cooper, Eugene V. Osteoporosis International.2023; 34(9): 1501. CrossRef
17. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis Mingwei Hu, Yifan Zhang, Jianjun Guo, Cuicui Guo, Xue Yang, Xue Ma, Hao Xu, Shuai Xiang Frontiers in Endocrinology.2023;[Epub] CrossRef
18. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis Namki Hong, Sungjae Shin, Seunghyun Lee, Yumie Rhee Osteoporosis International.2023; 34(12): 2059. CrossRef
19. Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part II) E. Carlos Rodriguez-Merchan, Alonso Moreno-Garcia, Hortensia De la Corte-Rodriguez SurgiColl.2023;[Epub] CrossRef
20. The efficacy of denosumab in Korean male patients with osteoporosis Chaiho Jeong, Jeonghoon Ha, Jinyoung Kim, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek The Korean Journal of Internal Medicine.2022; 37(5): 1011. CrossRef
21. Update on trabecular bone score Telma Palomo, Patricia Muszkat, Fernanda G. Weiler, Patricia Dreyer, Cynthia M. A. Brandão, Barbara C. Silva Archives of Endocrinology and Metabolism.2022; 66(5): 694. CrossRef